Hildegund C Ertl

Title: Hildegund C Ertl: Innovator in Vaccine Development

Introduction

Hildegund C Ertl is a prominent inventor based in Villanova, PA (US), known for her significant contributions to the field of vaccine development. With a total of 3 patents, she has made remarkable strides in the use of recombinant adenoviruses for vaccination purposes.

Latest Patents

Ertl's latest patents include the "Replication-defective adenovirus human type 5 recombinant as a vaccine" and "Replication-defective adenovirus human type 5 recombinant as a rabies." These innovations provide a method of vaccinating humans or animals against rabies by administering a replication-defective recombinant adenovirus. This virus contains a complete deletion of its E1 gene and at least a partial deletion of its E3 gene. The virus also includes a sequence comprising a non-adenovirus promoter that directs the replication and expression of DNA encoding the rabies virus G protein. When administered, this recombinant virus elicits a substantially complete protective immune response against the rabies virus.

Career Highlights

Throughout her career, Hildegund C Ertl has worked with esteemed institutions such as The Wistar Institute of Anatomy & Biology and the University of Pennsylvania. Her work has been pivotal in advancing the understanding and application of adenoviral vectors in vaccine development.

Collaborations

Ertl has collaborated with notable professionals in her field, including James M Wilson, enhancing the impact of her research and innovations.

Conclusion

Hildegund C Ertl's contributions to vaccine development through her innovative patents and collaborations highlight her as a key figure in the field. Her work continues to influence the future of immunization strategies.